<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02208297</url>
  </required_header>
  <id_info>
    <org_study_id>843</org_study_id>
    <nct_id>NCT02208297</nct_id>
  </id_info>
  <brief_title>Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</brief_title>
  <official_title>Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38% Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate
      (LE) ophthalmic gel, 0.38% (BID)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate
      (LE) ophthalmic gel, 0.38% (BID) for the treatment of inflammation and pain following
      cataract surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of AC Cells</measure>
    <time_frame>Visit 5 (Postoperative Day 8)</time_frame>
    <description>Participants with complete resolution of anterior chamber (AC) cells (cell score = 0) in the study eye</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>Visit 5 (Postoprative Day 8)</time_frame>
    <description>Participants with Grade 0 pain in the study eye</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of AC Cells</measure>
    <time_frame>At each study visit through Visit 6 (Day 15)</time_frame>
    <description>Participants with complete resolution of AC cells (cell score = 0) in the study eye at each on-treatment visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>At each study visit through Visit 6 (Day 15)</time_frame>
    <description>Participants with Grade 0 pain (no pain) in the study eye at each on-treatment visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of AC Flare</measure>
    <time_frame>At each study visit through Visit 6 (Day 15)</time_frame>
    <description>Participants with complete resolution of AC flare in the study eye at each on-treatment visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of AC Cells and Flare</measure>
    <time_frame>At each study visit through Visit 6 (Day 15)</time_frame>
    <description>Participants with complete resolution of AC cells and flare in the study eye at each on-treatment visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of AC Cells and Flare</measure>
    <time_frame>At each study visit through Visit 6 (Day 15)</time_frame>
    <description>Change from baseline in AC cells and flare, combined and separately, at each follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Failures</measure>
    <time_frame>Visit 5 (Postoperative Day 8)</time_frame>
    <description>Proportion of treatment failures at Visit 5 (Postoperative Day 8)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">322</enrollment>
  <condition>Inflammation</condition>
  <condition>Pain</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Loteprednol Etabonate Gel (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loteprednol Etabonate Gel 0.38% administered two times daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel (BID)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle gel administered two times daily (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol Etabonate Gel (BID)</intervention_name>
    <description>One drop of LE gel instilled into the study eye two times per day (BID) for 14 days</description>
    <arm_group_label>Loteprednol Etabonate Gel (BID)</arm_group_label>
    <other_name>Lotemax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Gel (BID)</intervention_name>
    <description>One drop of vehicle gel instilled into the study eye two times per day (BID) for 14 days</description>
    <arm_group_label>Vehicle Gel (BID)</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Visit 1 (Screening Visit)

          -  Be willing and able to comply with all treatment and follow-up/study procedures.

          -  Be a candidate for routine, uncomplicated cataract surgery.

        Visit 3 (Postoperative Day 1)

          -  Have undergone routine, uncomplicated cataract surgery (phaco-emulsification with
             posterior chamber intraocular lens (IOL) implantation, not combined with any other
             surgery) in the study eye.

          -  Have â‰¥ Grade 2 anterior chamber (AC) cells (6-15 cells) in the study eye.

        Exclusion Criteria:

          -  Have a severe/serious ocular condition or history/presence of chronic generalized
             systemic disease that the Investigator feels might increase the risk to the subject or
             confound the result(s) of the study.

          -  Have known hypersensitivity or contraindication to the study drug(s) or their
             components.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Vittitow</last_name>
    <role>Study Director</role>
    <affiliation>Valeant/Bausch &amp; Lomb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Incorporated</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2014</study_first_submitted>
  <study_first_submitted_qc>August 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2014</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

